Edition:
United States

Evolus Inc (EOLS.OQ)

EOLS.OQ on NASDAQ Stock Exchange Global Market

14.01USD
16 Oct 2018
Change (% chg)

$0.86 (+6.54%)
Prev Close
$13.15
Open
$13.22
Day's High
$14.70
Day's Low
$13.13
Volume
137,968
Avg. Vol
133,841
52-wk High
$39.50
52-wk Low
$6.78

Latest Key Developments (Source: Significant Developments)

Evolus Receives Acceptance Of FDA BLA Resubmission For Dwp-450
Wednesday, 29 Aug 2018 08:01am EDT 

Aug 29 (Reuters) - Evolus Inc ::EVOLUS RECEIVES ACCEPTANCE OF FDA BLA RESUBMISSION FOR DWP-450.EVOLUS INC - FDA CONSIDERED RESUBMISSION A CLASS 2 RESPONSE AND HAS ASSIGNED A FEBRUARY 2, 2019 ACTION DATE PER PRESCRIPTION DRUG USER FEE ACT.  Full Article

Evolus Announces Update With DWP-450 Regulatory Submissions
Wednesday, 16 May 2018 08:29am EDT 

May 16 (Reuters) - Evolus Inc ::EVOLUS ANNOUNCES PROGRESS WITH DWP-450 REGULATORY SUBMISSIONS.EVOLUS INC - CONFERENCE CALL SCHEDULED FOR 8:30AM ET / 5:30AM PT.EVOLUS INC - EVOLUS RECEIVES FDA COMPLETE RESPONSE LETTER WITH COMMENTS ISOLATED TO CMC ITEMS.EVOLUS INC - PLANS TO UTILIZE DAEWOONG FACILITY TO SUPPORT COMMERCIAL PRODUCTION FOLLOWING ANTICIPATED APPROVAL OF DWP-450..EVOLUS INC - FDA ISSUES FAVORABLE EIR LETTER RELATED TO MANUFACTURING FACILITY.EVOLUS INC - DWP-450 MANUFACTURING FACILITY IS FULLY VALIDATED BY DAEWOONG UNDER CURRENT GOOD MANUFACTURING PRACTICE REQUIREMENTS.EVOLUS INC - IN CRL, DEFICIENCIES CITED BY FDA WERE ISOLATED TO ITEMS RELATED TO CHEMISTRY, MANUFACTURING, AND CONTROLS PROCESSES.EVOLUS INC - EXPECTS TO RESPOND TO FDA ABOUT CRL WITH A COMPLETE SUBMISSION TO FDA WITHIN 90 DAYS.EVOLUS INC - LOOK FORWARD TO WORKING CLOSELY WITH FDA AND REMAIN COMMITTED TO BRINGING DWP-450 TO MARKET BY SPRING 2019.EVOLUS INC - DWP-450 MANUFACTURING FACILITY HAS CAPACITY EXPECTED TO MEET ANTICIPATED PRODUCT DEMAND.  Full Article

Evolus Reports Q1 Loss Per Share $0.30
Thursday, 10 May 2018 04:01pm EDT 

May 10 (Reuters) - Evolus Inc ::EVOLUS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.30.Q1 EARNINGS PER SHARE VIEW $-0.24 -- THOMSON REUTERS I/B/E/S.  Full Article

Evolus Appoints Allergan Aesthetics Head As President And Chief Executive Officer
Monday, 7 May 2018 07:01am EDT 

May 7 (Reuters) - Evolus Inc ::EVOLUS APPOINTS ALLERGAN AESTHETICS HEAD AS PRESIDENT AND CHIEF EXECUTIVE OFFICER.SAYS DAVID MOATAZEDI APPOINTED CEO AND PRESIDENT.MOATAZEDI WILL SUCCEED MURTHY SIMHAMBHATLA.  Full Article